Jason Efstathiou, Professor of Radiation Oncology at Harvard Medical School, posted on X:
“Looking forward to PTCOG next month, where I will be discussing the PARTIQoL trial in a plenary session.
PARTIQoL is a major win for radiation oncology and, most importantly, for patients.
What did the Phase 3 trial comparing proton therapy and IMRT in prostate cancer reveal?
Both approaches provided equally high tumor control rates and no differences in patient-reported quality of life for patients with localized low- and intermediate-risk prostate cancer. Watch the full discussion.”
Further Reading: 63rd Annual PTCOG Conference.